These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34355333)

  • 1. PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Kemuriyama K; Sasaki Y; Imai K; Maeda E; Minamiya Y
    Ann Surg Oncol; 2022 Feb; 29(2):1336-1346. PubMed ID: 34355333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
    Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between prognosis and lymph node status using
    Ohsawa M; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Yoshikawa T; Hirohata R; Kitasaki N; Okada M
    World J Surg; 2024 Mar; 48(3):650-661. PubMed ID: 38686781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
    Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
    Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
    J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of
    Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
    Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with ¹⁸F-fluorodeoxyglucose positron emission tomography-positive lymph nodes.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Higuchi I; Takiguchi S; Fujiwara Y; Doki Y
    Surg Today; 2015 Mar; 45(3):335-45. PubMed ID: 24969049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
    Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
    Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Rather than Pathological Response to Preoperative Chemoradiotherapy Is a Stronger Predictor of Survival in cStage IIB-IV Esophageal Cancer.
    Motoyama S; Sato Y; Maruyama K; Usami S; Yoshino K; Nakatsu T; Sasaki T; Wakita A; Kawakita Y; Liu J; Anbai A; Ishiyama K; Saito H; Minamiya Y
    Anticancer Res; 2017 Aug; 37(8):4189-4194. PubMed ID: 28739705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer.
    Zschaeck S; Li Y; Bütof R; Lili C; Hua W; Troost ECG; Beck M; Amthauer H; Kaul D; Kotzerke J; Baur ADJ; Ghadjar P; Baumann M; Krause M; Hofheinz F
    Int J Cancer; 2020 Sep; 147(5):1427-1436. PubMed ID: 32010957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.